Guggenheim starts Edgewise with Buy on ‘compelling entry point’

Guggenheim analyst Debjit Chattopadhyay initiated coverage of Edgewise Therapeutics (EWTX) with a Buy rating and $41 price target The company has two small molecules in mid to late-stage clinical development: EGD-7500 for obstructive and non-obstructive hypertrophic cardiomyopathy, and sevasemten for Duchenne muscular dystrophy, the analyst tells investors in a research note. The firm says that with multiple readouts over the next 12-months, and cash into 2028, Edgewise’s current $1B enterprise value “offers a compelling entry point.”